Journal Watch · Proceedings of the National Academy of Sciences (PNAS) · 2026
Avoidance of MAIT cells is an essential determinant of <i>Listeria</i> monocytogenes pathogenesis.
These findings reveal the importance of MAIT cell evasion during <i><i>L. monocytogenes</i></i> infection and highlight the therapeutic potential of engineered <i><i>L. monocytogenes</i></i> to activate and harness MAIT cells for protection against infectious disease and cancer.
TL;DR
These findings reveal the importance of MAIT cell evasion during <i><i>L. monocytogenes</i></i> infection and highlight the therapeutic potential of engineered <i><i>L. monocytogenes</i></i> to activate and harness MAIT cells for protection against infectious disease and cancer.
Key findings
- We also assessed the therapeutic potential of <i><i>L. monocytogenes</i></i>-<i>ribDEAHT-</i> stimulated MAIT cells in both infectious disease and cancer mouse models.
- Therapeutic administration of <i><i>L. monocytogenes</i></i>-<i>ribDEAHT</i> provided protection against <i>Francisella tularensis</i> in the lungs and inhibited tumor growth even in the absence of CD8<sup>+</sup> T cells.
- These findings reveal the importance of MAIT cell evasion during <i><i>L. monocytogenes</i></i> infection and highlight the therapeutic potential of engineered <i><i>L. monocytogenes</i></i> to activate and harness MAIT cells for protection against infectious disease and cancer.
What they did
Here, we show that <i><i>L. monocytogenes</i></i> strains engineered to produce riboflavin (<i><i>L. monocytogenes</i></i>-<i>ribDEAHT</i>) are attenuated in wild-type mice but fully virulent in MAIT cell-deficient mice. Infection with <i><i>L. monocytogenes</i></i>-<i>ribDEAHT</i> prompted rapid and robust MAIT cell expansion in multiple tissues and required the cytolytic effector perforin to eliminate infected cells in vivo and in vitro.
Full abstract (original)
Background: Mucosal-associated invariant T (MAIT) cells are among the most conserved and abundant innate-like T cells in humans that recognize microbial-derived riboflavin precursors and elicit potent antimicrobial responses. The foodborne pathogen <i><i>Listeria</i> monocytogenes</i> is a broad host-range facultative intracellular pathogen that lacks the riboflavin biosynthetic pathway, leading us to hypothesize that this deficiency is pathoadaptive and allows the pathogen to evade MAIT cells.
What they did: Here, we show that <i><i>L. monocytogenes</i></i> strains engineered to produce riboflavin (<i><i>L. monocytogenes</i></i>-<i>ribDEAHT</i>) are attenuated in wild-type mice but fully virulent in MAIT cell-deficient mice. Infection with <i><i>L. monocytogenes</i></i>-<i>ribDEAHT</i> prompted rapid and robust MAIT cell expansion in multiple tissues and required the cytolytic effector perforin to eliminate infected cells in vivo and in vitro.
Results & conclusions: We also assessed the therapeutic potential of <i><i>L. monocytogenes</i></i>-<i>ribDEAHT-</i> stimulated MAIT cells in both infectious disease and cancer mouse models. Therapeutic administration of <i><i>L. monocytogenes</i></i>-<i>ribDEAHT</i> provided protection against <i>Francisella tularensis</i> in the lungs and inhibited tumor growth even in the absence of CD8<sup>+</sup> T cells. These findings reveal the importance of MAIT cell evasion during <i><i>L. monocytogenes</i></i> infection and highlight the therapeutic potential of engineered <i><i>L. monocytogenes</i></i> to activate and harness MAIT cells for protection against infectious disease and cancer.
Abstract © the authors / Proceedings of the National Academy of Sciences (PNAS) (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1073/pnas.2601925123 · PubMed 42258727.
Why it matters for pharma & biotech
- Relevant to General & Medicine teams tracking Proceedings of the National Academy of Sciences (PNAS) for new targets, mechanisms and biomarkers.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Proceedings of the National Academy of Sciences (PNAS) study find?
These findings reveal the importance of MAIT cell evasion during <i><i>L. monocytogenes</i></i> infection and highlight the therapeutic potential of engineered <i><i>L. monocytogenes</i></i> to activate and harness MAIT cells for protection against infectious disease and cancer.
What type of study is this?
It is a preclinical (animal / model) study, published in Proceedings of the National Academy of Sciences (PNAS) in 2026. Here, we show that <i><i>L.
Where can I read the original paper?
The original is at the publisher via DOI 10.1073/pnas.2601925123. PubMed ID: 42258727. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/avoidance-of-mait-cells-is-an-essential-determinant-of-lt-i-gt-listeria-925123/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides